Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for Eli Lilly & Co
74.18
-0.14 (-0.19%)
Feb 8 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 72.83 - 74.58
52 week 68.31 - 92.85
Open 73.55
Vol / Avg. 4.35M/5.27M
Mkt cap 82.24B
P/E 32.82
Div/yield 0.51/2.75
EPS 2.26
Shares 1.11B
Beta 0.20
Inst. own 77%
May 3, 2016
Eli Lilly and Co Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
Apr 26, 2016
Q1 2016 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Apr 26, 2016
Q1 2016 Eli Lilly and Co Earnings Call - 9:00AM EDT - Add to calendar
Mar 8, 2016
Eli Lilly and Co at Cowen Health Care Conference - 8:40AM EST - Add to calendar
Feb 10, 2016
Eli Lilly and Co at Leerink Partners Global Healthcare Conference - 11:30AM EST - Add to calendar
Jan 28, 2016
Q4 2015 Eli Lilly and Co Earnings Release
Jan 28, 2016
Q4 2015 Eli Lilly and Co Earnings Call - Webcast
Jan 12, 2016
Eli Lilly and Co at JPMorgan Healthcare Conference
Jan 5, 2016
Eli Lilly and Co 2016 Financial Guidance Conference Call
Dec 8, 2015
Eli Lilly and Co Alzheimer's Disease Review
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 8.90% 12.07%
Operating margin 7.44% 13.47%
EBITD margin - 18.00%
Return on average assets - -
Return on average equity - -
Employees 39,135 -
CDP Score - 85 B

Address

Lilly Corporate Ctr
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company's products are sold in approximately 120 countries. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 50
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 55
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 61
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 46
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 49
Bio & Compensation  - Reuters
Darren J. Carroll Senior Vice President - Corporate Business Development
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 48
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 50
Bio & Compensation  - Reuters